NovoCure (NASDAQ:NVCR) Releases Earnings Results, Beats Expectations By $0.19 EPS

NovoCure (NASDAQ:NVCR) released its quarterly earnings data on Thursday. The medical equipment provider reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.19, FiscalAI reports. The company had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative net margin of 27.66% and a negative return on equity of 50.29%. NovoCure’s revenue was up 8.2% compared to the same quarter last year. During the same period last year, the business earned ($0.61) earnings per share.

Here are the key takeaways from NovoCure’s conference call:

• Novocure received FDA approval for Optune Pax for locally advanced pancreatic cancer, has begun U.S. launch activities, and filed regulatory applications in Europe and Japan.
• The company reported record 2025 net revenue of $655 million (Q4 revenue $174M) and issued 2026 guidance of $675M–$705M, while targeting adjusted EBITDA of –$20M to break even, reflecting a push toward profitability.
• Several near-term clinical catalysts are scheduled for 2026, including top-line readouts from PANOVA‑4 next month and the Phase 3 TRIDENT trial in Q2, plus expected completion of KEYNOTE‑D58 enrollment by year-end.
• Despite revenue growth, Novocure reported a full‑year net loss of $136 million and negative adjusted EBITDA (‑$34M for 2025), sees pressured gross margins (mid‑70s expected in 2026), and has drawn on credit while carrying $448 million in cash after repaying convertible notes.
• Leadership and operational changes include the resignation of the Chief Medical Officer and consolidation of scientific and clinical teams under Chief Innovation Officer Uri Weinberg, and a briefly suspended Medicare billing privilege that was promptly reinstated.

NovoCure Price Performance

Shares of NVCR traded down $1.24 during midday trading on Thursday, reaching $13.75. The stock had a trading volume of 5,490,062 shares, compared to its average volume of 2,907,818. The company has a current ratio of 1.55, a quick ratio of 1.50 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -8.54 and a beta of 0.73. The company’s 50-day moving average is $12.71 and its 200 day moving average is $12.63. NovoCure has a 12-month low of $9.82 and a 12-month high of $21.55.

Analysts Set New Price Targets

NVCR has been the subject of a number of recent analyst reports. Wedbush restated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a research report on Thursday, January 15th. Evercore set a $20.00 target price on NovoCure in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Finally, HC Wainwright boosted their price objective on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, NovoCure currently has an average rating of “Hold” and a consensus target price of $26.93.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Empowered Funds LLC bought a new stake in shares of NovoCure in the 4th quarter worth approximately $33,000. Kestra Advisory Services LLC purchased a new position in NovoCure in the 4th quarter worth $49,000. Larson Financial Group LLC lifted its stake in NovoCure by 662.1% in the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in NovoCure during the first quarter valued at about $87,000. Finally, Headlands Technologies LLC bought a new position in shares of NovoCure during the second quarter valued at about $88,000. 84.61% of the stock is currently owned by institutional investors.

NovoCure News Summary

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Medicare billing for NovoCure was restored, removing a key reimbursement overhang that had pressured near‑term revenue recognition and cash collection; this supports visibility into U.S. revenue and was cited by the market as a major positive catalyst. Novocure stock jumps after Medicare billing restored
• Positive Sentiment: Q4 results beat on EPS (loss of $0.22 vs. consensus -$0.41) and revenue was essentially in line at ~$174.4M (+8% YoY). The smaller-than-expected loss and steady top‑line growth reduce near‑term downside risk versus prior quarters. NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Management set FY‑2026 revenue guidance of $675M–$705M, modestly above street revenue consensus (~$670M), which signals expected continued growth and gives investors a clearer revenue trajectory for the year. Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
• Positive Sentiment: HC Wainwright raised its price target to $49 and reiterated a Buy rating, a high-profile analyst endorsement that could attract buyers given the large upside from current levels. Benzinga coverage of HC Wainwright PT raise
• Neutral Sentiment: Earnings‑call commentary highlighted record revenue and strategic growth plans (clinical and commercial expansion) but also discussed operational challenges and execution risks that management must resolve to sustain margin improvement — mixed signal for investors. NovoCure Q4 2025 Earnings Call Transcript Earnings call highlights
• Negative Sentiment: Despite the operational positives, NovoCure remains unprofitable (negative net margin and ROE) and analysts still model negative full‑year EPS; execution risk on margins and path to profitability keeps valuation under pressure. Zacks summary of Q4 results and financial metrics

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.